Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide

Molly G Minze1
Lisa M Chastain2

1School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, 2Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA

Abstract: The global burden of type 2 diabetes is estimated to currently affect over 350 million people worldwide and is anticipated to continue increasing over the next 20 years. Current treatment guidelines recommend the choice of pharmacotherapy based upon patient-specific parameters, with combination therapy for patients with a hemoglobin A1c level ≥9%. A new combination therapy of insulin degludec + liraglutide provides a long-acting basal insulin with a glucagon-like peptide agonist. In clinical trials, this combination product has reduced hemoglobin A1c and fasting plasma glucose more than the individual agents alone. Further advantages observed with this combination include weight loss and decrease in hypoglycemia compared to basal insulin alone.

Keywords: insulin degludec, liraglutide, type 2 diabetes, basal insulin, glucagon-like peptide agonist, injectable therapies

Introduction

The global burden of type 2 diabetes is estimated to currently affect approximately 387 million people worldwide with a prevalence of 8.3% of the worldwide population.1 This rate is expected to increase by an additional 205 million people worldwide by 2035. Individualized patient treatment approaches are endorsed in the most recent recommendations from the American Diabetes Association, American Association of Clinical Endocrinologists, and the UK National Institute for Healthcare and Excellence. The choice of therapy is contingent on patient-specific attributes and needs, which encourages providers to use oral pharmacotherapies such as metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, or injectable therapies, including glucagon-like peptides (GLP-1) or insulin therapy.2–4 Despite concerted efforts and guidance, up to 49% of patients do not meet their hemoglobin A1c (HbA1c), blood pressure, or lipid goal.5 Initial combination therapy is recommended for patients with higher HbA1c levels at baseline (ie, ≥9%) who are unlikely to gain control with monotherapy.2 Combination therapy using basal insulin, in addition to a GLP-1 agonist, has been effective and equal to basal and prandial insulin.6–8

A search was performed within PubMed using the key terms “insulin degludec” and “liraglutide” and “liraglutide”. This review explores the combination use of insulin degludec in fixed combination with liraglutide.

Pharmacology

Basal insulin and GLP-1 agonists

Basal insulin provides sustained glucose control through its long duration of action and steady exogenous insulin delivery without a peak.9 Glucagon-like protein-1 agonists are
designed to mimic the incretin hormone GLP-1 and gastric inhibitor polypeptide, both of which are produced after eating a meal. These incretin hormones promote insulin secretion and suppress the production of glucagon through a glucose-dependent mechanism. Basal insulin reduces fasting and post absorptive blood glucose, whereas GLP-1 agonists decrease postprandial glucose via gastric emptying inhibition, stimulation of glucose-dependent insulin secretion, and suppression of glucagon production.

Insulin degludec, a new basal insulin analog administered subcutaneously once daily, provides a constant and steady insulin exposure with less within-patient variability compared with insulin detemir and insulin glargine. Insulin degludec has been designed as an ultra-long-acting basal insulin that improves the following limitations of other marketed basal insulins: short half-life compared to duration of action, restriction of patient lifestyle secondary to need for consistent timing of injection from day-to-day, and improved simulation of physiologic distribution of endogenous insulin. After subcutaneous injection, insulin degludec forms a soluble depot with slow and continuous absorption secondary to dihexamer self-association into multihexamer chains.

In special populations such as the elderly, renally impaired, and heparically impaired, insulin degludec’s pharmacokinetic and pharmacodynamic properties are preserved. Adverse effects observed with insulin degludec are consistent with other insulin products and include hypoglycemia, and weight gain. Additionally, a case report using insulin degludec successfully in an otherwise insulin allergic patient has been reported in the literature.

Degludec and liraglutide combination

When basal insulin and a GLP-1 agonist are used in combination, they target complementary blood glucose-lowering mechanisms. Degludec and liraglutide have recently been formulated in combination together as a once-daily single injection prefilled pen with degludec 100 units/mL + liraglutide 3.6 mg/mL for use in type 2 diabetes. Degludec + liraglutide (IDegLira) is approved in the European Union and has filed for approval in the USA. In a pharmacokinetic study, IDegLira had preserved kinetic properties compared to monotherapy of the individual agents. Also, the pharmacodynamics properties of the combination product have remained the same as those of the...
individual products. Like the individual products, the most common adverse effects seen with the combination agent are hypoglycemia and gastrointestinal symptoms, such as nausea, diarrhea, vomiting, and constipation.

**Clinical studies**

**Efficacy**

Several clinical trials have evaluated the efficacy of the combination of insulin degludec + liraglutide for the treatment of diabetes in differing background antidiabetic regimens (insulin naïve, patients previously treated with metformin, or patients previously on basal insulin).

DUAL-I was a treat-to-target, open-label, noninferiority trial evaluating efficacy (change in HbA1c after 26 weeks) of IDegLira compared to its components in insulin-naïve patients. Subjects with type 2 diabetes, HbA1c 7%–10%, BMI ≤40 kg/m² treated with metformin, with or without pioglitazone were randomized to once-daily IDegLira (n=834), insulin degludec (n=414), or liraglutide 1.8 mg/day (n=415). IDegLira and degludec were titrated weekly to fasting plasma glucose (FPG) of 72–90 mg/dL; however, IDegLira was capped at a maximum of 50 dose steps (50 units IDeg +1.8 mg liraglutide). IDegLira produced a significantly greater HbA1c reduction from baseline (−1.9%) compared with IDeg (−1.4% from baseline) or liraglutide (−1.3%). IDegLira was noninferior to insulin degludec (estimated treatment difference [ETD], −0.47%, 95% confidence interval [CI] [−0.58 to −0.36], P<0.0001) and superior to liraglutide (ETD −0.64%, 95% CI [−0.75 to −0.53], P<0.0001). DUAL-I also saw greater numbers of patients achieving HbA1c <7% in the IDegLira group after 26 weeks compared to IDeg (81% vs 65%, P<0.0001) or liraglutide (60%, P<0.001). Another benefit seen in this trial was a weight loss of 0.5 kg in the patients in the IDegLira group compared with a weight increase of 1.6 kg in patients in the IDeg group (P<0.0001). Lastly, at 26 weeks, mean insulin dose was 28% lower with IDegLira than with IDeg (38 vs 53 units, P<0.0001).

DUAL-I trial authors also published data from the extension trial, which followed subjects for an additional 26 weeks to assess the sustainability of the treatment response of IDegLira over 52 weeks. The 52-week secondary endpoints included change from baseline in HbA1c, percentage of patients reaching HbA1c <7% and ≤6.5% as well as changes from baseline in FPG, body weight, insulin dose, and 9 point self monitoring blood glucose (SMBG) profiles. There were 1,311 patients who continued into the DUAL-I extension phase (665 IDegLira/333 IDeg/313 Lira), which was approximately 78% of the population from the original trial. At the end of the 52 weeks, mean HbA1c concentration remained significantly lower for the IDegLira group compared to the IDeg group (−1.84% vs −1.40%, P<0.0001) and liraglutide (−1.21%, P<0.0001). Additionally, a greater number of subjects in the extension trial achieved maintained HbA1c <7% if receiving IDegLira (78.2%) compared to IDeg (62.5%) or liraglutide alone (56.5%). Also noted in the extension trial was that body weight remained relatively stable throughout the extension with IDegLira (−0.4 kg) and liraglutide (−3.0 kg), but increased by a total of 2.3 kg from baseline in the IDeg group. Mean daily insulin doses of the insulin degludec and liraglutide components were significantly lower in the IDegLira (39±13 units/1.42±0.5 mg) group when compared with either product alone (62±42 units insulin degludec, 1.8±0.7 mg liraglutide).

The DUAL-II trial set out to determine the contribution of the liraglutide component of IDegLira in a 26-week open-label study comparing diabetics (HbA1c 7.5%–10.0%, BMI ≥27 kg/m², uncontrolled on 20–40 units of basal insulin + metformin ± secretagogues) randomized to IDegLira + metformin (n=199) or IDeg + metformin (n=199). At randomization, participants were allowed to remain on metformin while basal insulin was switched to either IDeg 16 units or IDegLira 16 dose steps (16 units degludec +0.6 mg liraglutide). Doses were adjusted biweekly to a target of FPG 72–90 mg/dL and were capped at either 50 units or 50 dose steps to evaluate the impact of the liraglutide component to glycemic control. At study end, IDegLira achieved a 1.9% HbA1c reduction compared to 0.9% reduction in IDeg group (ETD 1.1%, 95% CI [−1.3 to −0.8], P<0.0001) despite equivalent IDeg doses (−45 units). Patients in the IDegLira group had a greater chance of achieving HbA1c <7% (60% IDegLira vs 23% IDeg, with a higher estimated odds of achieving goal, P<0.0001) as well as the percentage of patients to achieve this goal without hypoglycemia or weight gain (40% IDegLira vs 8.5% IDeg, P<0.0001). FPG and 9 point SMBGs were also significantly lower in IDegLira group. Lastly, 2.7 kg weight reduction was seen in the IDegLira group vs no change in the IDeg group (P<0.001).

BEGIN: VICTOZA ADD-ON was an open-label, treat-to-target study investigating the efficacy and safety of adding liraglutide once-daily vs insulin aspart once-daily at largest meal to insulin degludec + metformin. Study subjects were randomized to IDeg + Lira (n=88) or IDeg + IAсп (n=89) for 26 weeks, targeting FPG 71–89 mg/dL. The primary endpoint in this trial was a change in HbA1c after 26 weeks
with secondary endpoints, including change in FPG, body weight, and 9 point SMBG profile. At study end, patients in the IDEg + Lira achieved HbA1c reduction of 0.76% points compared to 0.39% point reduction in IDEg + IAsp (ETD -0.32% points, 95% CI [-0.53 to -0.12], P=0.0024).

Between groups, there was no statistically significant difference in IDEg + Lira vs IDEg + IAsp achieving HbA1c <7% (58% vs 44.9%, respectively); however, there were significantly more patients in the IDEg + Lira group able to achieve HbA1c <7% without hypoglycemia (estimated odds ratio [OR] 5.57, 95% CI [2.67–11.63], P<0.001) and without hypoglycemia and weight gain (estimated OR 13.79, 95% CI [5.24–36.28], P<0.0001). No differences were seen between groups with respect to FPG and 9 point SMBG profiles; however, significant weight difference seen at 26 weeks with the IDEg + Lira group losing 2.8 kg compared to a 0.9 kg gain in body weight in the IDEg + IAsp group (P<0.0001). Although this study did not evaluate the combination product of insulin degludec and liraglutide, it did provide insight into potential benefits of adding a long-acting GLP-1 agonist to basal insulin compared to once-daily bolus insulin added to basal insulin.  

Freemantle et al describe a pooled analysis of the five completed clinical trials from the manufacturer of IDEgLira. Using patients from the DUAL-II trial and four other Novo Nordisk sponsored trials, an estimate of indirect treatment effects was obtained with the primary outcome of change in HbA1c from baseline to study end. Secondary outcomes included hypoglycemia, change in baseline body weight and BMI, and percentage of patients achieving HbA1c <7% with or without hypoglycemia or weight gain. The analysis compared basal insulin products with IDEgLira in patients with type 2 diabetes not controlled by basal insulin from the Novo Nordisk clinical trial database. The treatment outlined in four of the trials included insulin titration to a FPG target of 72–90 mg/dL (4–5 mmol/L), whereas the remaining trial reduced pretrial basal insulin doses by 20%, which is similar to current practice trends when liraglutide is added to basal insulin. A significant lowering of estimated HbA1c occurred in the IDEgLira group (−1.68%, 95% CI [−1.82 to −1.54]) than in the other groups, including: GLP-1+ basal insulin, basal-bolus insulin therapy, and uptitrated insulin glargine groups (−1.33%, 95% CI [−1.48 to −1.18]), basal-bolus insulin therapy (−1.39%, 95% CI [−1.64 to −1.13]), and uptitrated insulin glargine group (−1.03, 95% CI [−1.14 to −0.93]). Body weight and BMI also showed significant reductions in the IDEgLira group (body weight −2.88 kg, 95% CI [−3.39 to −2.27], BMI −1.02 kg/m², 95% CI [−1.19 to −0.84]) compared to all other groups. 

### Safety and tolerability data

The trials (DUAL-I, DUAL-I extension, DUAL-II, and BEGIN: VICTOZA ADD ON) also looked at the safety and tolerability of the combination of insulin degludec and liraglutide compared to the individual components. Tolerability outcomes generally included hypoglycemic episodes and gastrointestinal symptoms, while safety outcomes included pancreatitis and increased concentrations of amylase and lipase, or incidence of thyroid carcinoma. In DUAL-I, confirmed hypoglycemia was significantly greater in the IDEgLira group when compared to the liraglutide group (Estimated rate ratio [ERR] 7.61, 95% CI [5.17–11.21], P<0.0001) but less frequent than the IDEg group (ERR 0.68, 95% CI [0.53–0.87], P=0.0023). Similar results were seen in the DUAL-I extension trial with lower rates of confirmed hypoglycemia per 100-patient years of exposure (PYE) in the IDEgLira group when compared to IDEg (Rate ratio [RR] 0.63, P<0.0001) but greater rates of hypoglycemia when compared to the liraglutide group (RR 8.52, P<0.0001). Nocturnal hypoglycemia was greater in the IDEgLira group in the extension study when compared to liraglutide (RR 11.99, P<0.0001) but no significant differences were noted when compared to IDEg. DUAL-II study found a numerically greater incidence of confirmed hypoglycemia with the IDEgLira compared to IDEg alone, however, these results were not statistically significant (RR 0.66, P=0.13). Additionally, nocturnal hypoglycemia rates were low and similar between groups. Hypoglycemia results remain consistent, even in the BEGIN: VICTOZA ADD-ON trial, with a rate of confirmed hypoglycemia of 1.00 episode per PYE with IDEgLira compared to 8.15 episodes per PYE in IDEg + IAsp (ERR 0.13, 95% CI [0.08–0.21], P<0.0001) and nocturnal hypoglycemia identified at 0.17 per PYE in IDEgLira compared to 1.11 per PYE with IDEgAsp (ERR 0.14, 95% CI [0.05–0.40], P=0.0002). These results of hypoglycemic safety suggest that while the combination of IDEg + liraglutide might carry a higher risk of hypoglycemia compared to liraglutide or IDEg alone or IDEg plus bolus insulin, the risk of hypoglycemia is reduced, suggesting mitigation of the hypoglycemic effects even when targeting fairly strict glycemic goals. 

Aside from hypoglycemia there were additional adverse effects seen in these trials, associated with the drugs, specifically liraglutide, that might deter adherence for patients. In general, IDEgLira has been well tolerated, with adverse events (AEs) categorized as mild or moderate in
severity. The most frequently reported adverse effects were generally headache (−10% in most trials), nasopharyngitis (−9% in most trials), or gastrointestinal disorders.\textsuperscript{26–29} In DUAL-I, nausea occurred with greater frequency in the liraglutide group (20%) when compared to the IDEg (4%) or IDEgLira (9%) groups. The reduced level of nausea observed in the IDEgLira group was likely related to the overall slower dose escalation and lower ending dose. Per study investigators, a higher proportion of subjects withdrew from the liraglutide group for gastrointestinal (GI) AEs when compared to the IDEgLira or IDEg groups.\textsuperscript{26} In DUAL-I extension, AE reporting remained similar to the first 26 weeks, with overall lower rates of AEs reported with IDEgLira or IDEg compared to liraglutide (407.9 vs 383.3 vs 507.3 per 100 PYE, respectively) and specifically the incidence of nausea in the extension study remained consistent with the first 26 weeks.\textsuperscript{27} DUAL-II found similar results when comparing IDEgLira to IDEg, with nausea occurring in 6.5% and 3.5% of subjects, respectively, and was more frequent in the first 12 weeks. However, study authors indicated that there were no drug withdrawals due to GI side effects in this 26-week trial.\textsuperscript{28} Similarly, when comparing GI symptoms in the BEGIN: VICTOZA ADD ON trial, nausea was more frequent in the IDEg + Lira group at two distinct time points, one at baseline and another when liraglutide was titrated, but symptoms declined within 2 weeks. At study endpoint, only 3% of subjects in the IDEg + Lira reported nausea and there were no study drug discontinuations related to nausea.\textsuperscript{29}

In the Freemantle pooled analysis, overall rates of hypoglycemia and nonsevere hypoglycemia appeared significantly lower with IDEgLira (0.99, 95% CI [0.63–1.54], \(P=0.95\)) compared to IDEgLira vs basal-bolus (0.12, 95% CI [0.07–0.2], \(P<0.0001\)) and IDEgLira vs uptitrated glargine (0.43, 95% CI [0.3–0.62], \(P<0.0001\)) with severe hypoglycemia occurring too infrequently to show a meaningful statistical difference.\textsuperscript{30}

In addition to known and documented adverse effects, there are also noted safety concerns with the individual agents in this drug combination. The class of GLP-1 agonists is known to carry a risk of pancreatitis and medullary thyroid carcinomas, thus each of these trials were monitored for such incidence. With respect to the issue of pancreatitis or elevated amylase and or lipase levels, the results were somewhat mixed between these trials. In DUAL-I, 18 cases of pancreatitis occurred; however, only one of these was confirmed to be acute pancreatitis but was judged as unlikely related to study drug.\textsuperscript{26} In the DUAL-I EXTENSION, five cases of pancreatitis, two with IDEgLira (both treatment-emergent), two cases with liraglutide (one treatment-emergent), and one nontreatment-emergent case with IDEg were identified. Of these cases, only one was positively adjudicated in the liraglutide group and one in the insulin degludec group. This trial also followed trends of amylase and lipase levels in subjects over 52 weeks and found 16 events of increased lipase and/or amylase with only one adjudicated as increased pancreatitis in the liraglutide group.\textsuperscript{27} There were no thyroid medullary carcinomas reported in either the DUAL-I or extension trial.\textsuperscript{26,27} Similarly, DUAL-II did not find any confirmation of thyroid carcinoma or pancreatitis, but found greater changes in amylase and lipase in the IDEgLira group (seven vs two patients in IDEg), though no occurrence was associated with pancreatitis.\textsuperscript{28} In BEGIN-VICTOZA ADD ON only one case of pancreatitis occurred in the IDEg + IAsp arm (deemed unlikely to be related to either study drug) and no cases in the IDEg + Lira group.\textsuperscript{29}

Based on the data presented earlier, it appears that the addition of liraglutide to basal insulin degludec provides many potential benefits of diminishing some of the main side effects associated with basal insulin alone, such as weight loss and hypoglycemia. Additionally, the presence of the basal insulin allows for lower doses of GLP-1 agonist to reduce the impact of gastrointestinal side effects. Not only is this new option effective at glycemic reduction, but it also seems to be a safe option with low incidence of pancreatitis truly attributable to the combination. However, individual patient factors must be considered on a case by case basis, as the combination of insulin degludec + liraglutide might not be the optimal choice for all patients. When applying the clinical trial data, an ideal patient to receive insulin degludec + liraglutide would be one with disease progression who is no longer controlled with oral medications and basal insulin alone. It would seem prudent to consider the use of a GLP-1 agonist combined with basal insulin therapy when considering whether to add meal-time bolus insulin as the use of a GLP-1 analog would provide postprandial glycemic control to all meals, compared to stepwise addition ofbolus insulin, resulting in three separate injections for meals in addition to the basal insulin. In fact, many widely recognized diabetes treatment algorithms, such as American Diabetes Association and the American Academy of Clinical Endocrinology, now indicate the combination of basal insulin + GLP1 agonist be considered at this step.\textsuperscript{31,32} With the combination product of IDEgLira, the patient is able to receive both prandial and postprandial glucose reduction with only one injection.
Patient perspectives

Patients living with diabetes experience burdens and challenges from the disease that often negatively impact their health-related quality of life (QoL), such as higher rates of morbidity and mortality. Exogenous insulin does improve glucose control and can improve prognosis, but does not eliminate physical or psychosocial concerns of the disease. Common justifications that decrease QoL include fear of hypoglycemia, fear of self-injection, anxiety regarding inflexible or complex dosing regimens, and embarrassment of diagnosis. At this time, patient-centered perspectives with the use of degludec + liraglutide are not available. However, perspectives are available with the individual agents degludec and liraglutide, as presented in the paragraphs below.

In a meta-analysis of Phase III trials, health-related QoL scores were evaluated in patients with diabetes who received insulin degludec vs insulin glargine. Six trials included in the meta-analysis were Phase IIIa clinical trials with IDeg once-daily vs IGlar once-daily that included QoL analysis, and were randomized, controlled, open-label trials of 26 or 52 weeks that included a total of 4,001 patients. At baseline and end-of-trial, patients completed a Short Form 36 (SF-36) version-2 health questionnaire, where an increase in SF-36 score indicated improvement in health, but are not based on individual preference. The SF-36 scores were then converted to EuroQol-5D health utility scores, which can be interpreted in a range of −0.59 (worst health) to 1 (best health). The average age of the patient in the combined population within the six trials assessed was 56±11.7 years, with a duration of diabetes of 12±8.4 years, with HbA1c of 8.2±0.9 mmol/mol, FPG 166±54.1 mg/dL, and BMI of 30.0±5.3 kg/m². Significant improvement in EuroQol-5D scores was seen in the IDeg treatment groups of 0.005, (95% CI [0.0006–0.009]) compared to IGlar (P<0.024). These results show a statistically significant improvement in health utility with IDeg compared to IGlar, although the authors admit it is a modest improvement.

In patients with type 1 diabetes, health status was assessed through SF-36 during a randomized, 16-week open-label trial. Patients with type 1 diabetes with an average age of 45.8 years, HbA1c 8.4%, and BMI 26.9 kg/m² were randomized to receive glargine 100 U/mL (n=59) or degludec 100 U/mL (n=59), along with mealtime insulin aspart. The mental score improved significantly in the degludec group after 16 weeks as compared to the glargine group by 3.01 (95% CI 0.32–5.7). Contributing to this increase was social functioning by 8.04 (significant but moderate difference, 95% CI 1.89–14.18), and an increase in the mental health domain by 2.46 (significant but small-to-medium difference, 95% CI 0.1–4.82). The physical component score did not show statistical significance between groups with +0.66 difference (95% CI −2.3 to −3.62). Insulin degludec improved SF-36 mental health scores in type 1 patients receiving insulin degludec compared to those receiving insulin glargine.

Patient medication adherence has not been researched with the combination of insulin degludec and liraglutide; however, adherence to each component individually has been investigated. A single-center study evaluated adherence to insulin therapy through analyzing treatment persistence and daily adherence in patients with type 2 diabetes who were insulin naïve. A total of 433 patients with an average age of 55.5±13 years received basal, basal-bolus, or premixed insulin via pen device. Patients were phone-interviewed 6 months postinitiation of insulin. Insulin nonadherence occurred in 44.3% (n=192) of patients with an all-cause treatment discontinuation of 24% (n=104), and daily insulin nonadherence of 20.3% (n=88). Eighty-seven patients (20.1%) withdrew from treatment, with 75.9% of withdrawals were at the patient’s discretion. Patient nonpersistence occurred in 13.7% of patients and was based on a physician’s decision. In patients who were persistent to insulin therapy, daily insulin adherence resulted in lower daily insulin doses (P=0.03) and self-measured postprandial blood glucose readings (P=0.04). The premixed and basal insulin groups had improved treatment adherence compared with basal-bolus regimens (P=0.04).

Patient adherence and persistence to liraglutide once-daily in adult (age ≥18 years) type 2 diabetes (n=1,321) was studied in a retrospective cohort claims data analysis. Adherence was defined as proportion of days covered with a score of ≥0.8 deemed nonadherent, and nonpersistence was defined by a >90-day gap in therapy. The average proportion of days covered was 0.59 with patient adherence of 34% and over 12 months, 60% of patients were persistent. Characteristics of a patient achieving HbA1c goals were those who were adherent and persistent compared to those who were nonadherent and nonpersistent (HbA1c 8.08% vs 8.29%, P=0.033).

Conclusion

The combination of insulin degludec + liraglutide combines a new basal insulin analog with a GLP-1 agonist. Clinical trials provide data supporting improved glycemic targets (HbA1c, FPG) with this combination therapy more than with the individual products alone. Further favorable effects shown include weight loss, lower basal insulin dose, and with
less hypoglycemia than basal insulin alone. Safety concerns of pancreatitis and medullary thyroid carcinomas associated with the combination insulin degludec + liraglutide showed few cases of pancreatitis and no cases of medullary thyroid carcinomas within the clinical trials completed to date. Overall, the combination of insulin degludec + liraglutide provides beneficial HbA1c and blood glucose reduction in patients with type 2 diabetes.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


